Cullinan Therapeutics (CGEM) Cash from Operations (2020 - 2026)

Cullinan Therapeutics' Cash from Operations history runs 7 years deep, the most recent figure standing at 46045000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 6.7% year-over-year to 46045000.0 in Q1 2026; TTM through Mar 2026 was 178640000.0, a 18.93% decrease from a year earlier, with the FY2025 full-year figure at 175750000.0, down 20.95% from the prior year.
• Cash from Operations retreated to 46045000.0 in Q1 2026 per CGEM's latest filing, from 38109000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 18131000.0 in Q4 2023 and bottomed at 57609000.0 in Q2 2025.
• The 5-year median for Cash from Operations is 36626000.0 (2024), against an average of 36943352.94.
• Across the five-year window, Cash from Operations plunged 1346.07% in 2022 and jumped 37.19% in 2023, its largest moves.
• Year by year, Cash from Operations stood at 24983000.0 in 2022, then gained by 27.43% to 18131000.0 in 2023, then tumbled by 102.01% to 36626000.0 in 2024, then slipped by 4.05% to 38109000.0 in 2025, then dropped by 20.82% to 46045000.0 in 2026.
• Per Business Quant, the three latest CGEM Cash from Operations figures stand at 46045000.0 (Q1 2026), 38109000.0 (Q4 2025), and 36877000.0 (Q3 2025).